Positive Results Reported for Potential Humira Biosimilar

The comparative, confirmatory REFLECTIONS B538-02 study has met its primary objective by demonstrating equivalent efficacy, as measured by the American College of Rheumatology 20 response rate at week 12, between PF-06410293 and Humira . PF-06410293, a monoclonal antibody, is being developed as a potential biosimilar to Humira.